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The 2015 represent the deadline for the global tuberculosis (TB) targets set through the Mil-
lennium Development Goals (MDG). From 2016 and onward, new goals were set to end the
global TB epidemic via implementing new campaign entitled ‘‘the End TB Strategy”. The
major hurdle to end TB epidemic in several parts of the world is the emergence and spread
of drug resistant Mycobacterium tuberculosis (MTB) strains. The better understanding of the
actual global burden of drug resistant tuberculosis would feed into better implementing the
End TB Strategy. In this article we summarize the current knowledge on the patterns of
drug resistance tuberculosis cases in the Middle East countries. These countries are served
by the Eastern Mediterranean Regional Office (EMRO), one out of six regional offices of
World Health Organization. Middle East countries are characterized by geographic vicinity
and population’s interaction. However, they are dissimilar in several aspects such as econ-
omy and health infrastructures. Regarding economy, countries in this region are ranging
fromwealthy to very poor. Prevalence of tuberculosis and patterns drug resistance tubercu-
losis cases are also following variable trends within countries of this region. In almost all
Middle East countries, there is under-reporting of drug-resistance tuberculosis cases. There
are shortages in the infrastructures and facilities for detecting the pattern of drug-
resistance tuberculosis. For instance, sixout of 14 countries have neither in-country capac-
ity nor a linkage with a partner laboratory for second-line drug susceptibility testing and
only 4 countries have registered site performing Xpert MTB/RIF.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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The Middle East and its position within World Within the United Nations system, the directing and coor-
Health Organization regional offices
TheMiddle East is a term first used at the beginning of the last
century [1]. It has a loose geographic definition, but with
wealthy political usages [2]. Geographically, the Middle East
is a region extending from the western side of the Indian sub-
continent to the Eastern Mediterranean and from the Arabian
Peninsula in the South to Turkey in the North. There are 16
countries forming the Middle East, namely Egypt, Iran, Iraq,
Turkey, Saudi Arabia, Yemen, Syria, United Arab Emirates
(UAE), Jordan, Palestine, Lebanon, Oman, Kuwait, Qatar, Bah-
rain, and Israel [3]. According to the World Health Organiza-
tion (WHO) database, almost 400 million people,
approximately 5% of the world’s population, live in the Middle
East: Egypt (90 million), Iran (78 million), Turkey (78 million),
Iraq (35 million) and Saudi Arabia (31 million) being the most
populated countries [4]. Six countries are in the Gulf Cooper-
ation Council (GCC); Saudi Arabia, Qatar, Bahrain, Kuwait,
Oman, and UAE [5]. Saudi Arabia is the biggest country among
the GCC, followed by UAE (9.1 million), Oman (4.2 million),
Kuwait (3.8 million), Qatar (2.2 million), and the smallest is
Bahrain with population of 1.4 million [4].
Historically, several civilizations and religions have been
embraced in the Middle East and formed a framework for
human interactions [6]. Some of the human interactions could
have medical consequences, such as: waves of human migra-
tion and settlements; inter-marriage between civilizations;
numerous wars and political instabilities; as well as trading
and industry [3,7,8]. Since the beginning of 2011, uprisings and
dramatic political changes have swept the Middle East, with
major events occurring in Egypt, Syria, and some of the Gulf
states and Yemen [2]. The effect of these events on the health
systems needs to be addressed. Tuberculosis (TB) has been a
familiar disease in the Middle East since ancient times [9]. A
consistent external source of TB transmission is the substantial
numbers of people migrating to the Middle East for economic or
religious reasons [10]. Many of those immigrants or travelers are
coming to the Middle East from countries that are endemic for
multidrug-resistant (MDR) TB, such as South-East Asia, the
Indian subcontinent, the former Soviet Union, and East Africa
[11].dinating authority for public health in Middle East countries is
the WHO Eastern Mediterranean Regional Office (EMRO),
which is one of six regional offices. EMRO serves additional
countries (has 21 member states and Palestine; West Bank
and Gaza Strip; see: www.emro.who.int). Most of the available
data on the burden of MDR TB within EMRO countries are
based onWHO estimates, as no population-based representa-
tive surveys have been conducted yet in most of the coun-
tries. In most of the cases, data other than annual WHO
reports are obtained from small studies that are designed to
collect information from cases handled in referral hospitals,
which makes these studies unreliable sources of data. In con-
trast, WHO estimates are based on modeling systems, and
most of these contain discrepancies between the estimates
and detection rates for each country [12,13].TB profile of the Middle East
The methods used to estimate TB incidence in Middle East
countries are variable. In countries such as Iran, Syria, Jordan,
and Palestine, case notification data are combined with
expert opinion about case detection gaps (under-reporting
and underdiagnosis). In Turkey, Saudi Arabia, Qatar, Kuwait,
and Oman, notifications are adjusted by a standard amount
or measure of under-reporting from inventory studies (sur-
veys conducted to quantify the level of under-reporting of
detected TB cases, to account for case detection gaps). In
Egypt, Iraq, and Yemen, recent capture–recapture studies
were conducted (capture–recapture is a type of modeling
designed to permit quantification of the level of under-
reporting of diagnosis of cases) [14].
In 2014, a total of 58,252 TB cases were notified in the Mid-
dle East, and 96% of the cases were detected in seven coun-
tries (Iran, Iraq, Turkey, Egypt, Syria, Saudi Arabia, and
Yemen). The biggest contributor to the TB burden in this
region was Turkey, which comprised 22% of cases. Five coun-
tries reported a TB burden <25/100,000 population compared
to one country in 1990 [13], whereas two countries (Iraq and
Yemen) reported a burden >50/100,000. Within the countries
of the GCC in 2014, the total numbers of notified TB cases
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Oman, and 61 in UAE. Bahrain did not report any data to WHO
in 2014. The highest estimated incidence and prevalence were
in Qatar (29 and 37 per 100,000 population, respectively)
whereas the lowest were in UAE (1.6 and 2.7 per 100,000 pop-
ulation, respectively).
Brief history and definitions of drug resistance in
Mycobacterium tuberculosis
Resistance to antimicrobials is a natural phenomenon, never-
theless, in M. tuberculosis, resistance to anti-TB drugs is consid-
ered ‘‘man-made”, as it commonly results from artificial
selection of spontaneous drug resistance mutations during
inadequate or incomplete therapy [15–17]. The development
of resistance to anti-TB drugs was detected shortly after their
introduction (streptomycin) in 1947 [18,19]. Over the past
40 years, there has been an emergence and escalated recogni-
tion of several patterns of drug resistance in TB strains [15–
17]. Currently, there is a consensus definition for two important
drug-resistance patterns: MDR TB and extensively drug-
resistant (XDR) TB [15–17]. MDR TB is defined as resistance to
at least isoniazid and rifampicin; the two most effective and
less toxic first-line anti-TB drugs [20–22]. XDR TB is defined as
MDR TB that also has resistance to at least a fluoroquinolone
and one second-line injectable agent (amikacin, kanamycin,
and/or capreomycin); the two most potent classes of second-
line anti-TB drugs [23–26]. The definitions of drug-resistance
patterns are based on clinical, epidemiological, and laboratory
data. These data are validated by several recognized laborato-
ries. For instance, the XDR TB definition was chosen on the
basis of data from 14 Supranational TB Reference Laboratories
included drug susceptibility testing (DST) results of 18,225
patients collected from 48 countries in 2000–2004 [27].
Over time, newer anti-TB drug resistance patterns have
developed and spread. During the past 10 years, several pub-
lished studies reported the emergence of strains that were
shown to be resistant to all of the existing anti-TB drugs
[23–28]. These strains are hypothesized to be XDR TB, with
resistance to additional second-line TB drugs [23–26]. The def-
inition of drug-resistance patterns of TB beyond XDR is con-
troversial and subject to huge debate. In 2007, a new
acronym (XXDR TB = extremely drug-resistant TB) was sug-
gested to designate the resistance pattern in two isolates
recovered from cases in Italy [23]. Those two ‘‘XXDR-TB” cases
were shown to resist all first- and second-line drugs. Two
years later, a report from Iran was published describing the
characterization of strains that were resistant all known
anti-TB drugs [24]. The authors proposed the acronym totally
drug-resistant (TDR) TB to denote this pattern of resistance.
In 2012, a report from India described the isolation of TDR
TB from Indian patients [25]. Nevertheless, there is ongoing
debate on the selection of criteria to designate the level of
TB drug resistance beyond XDR TB [29].
Debate on TDR TB
The different authorities, including WHO, are hesitant to give
definitions for resistance beyond XDR TB [30–32]. The reasonsinclude issues surrounding reliability of the current DST
methods; the expected negative impact of the word ‘‘total”
on patients, contacts, and caregivers; and the sufficiency of
the available evidence and studies [31]. Furthermore, there
are several new drugs that will be released shortly or in the
foreseeable future, however, there is yet no reliable DST
developed to test their susceptibility [30]. The reported TDR
TB strains cannot be ignored as they are not only resistant
to all available anti-TB drugs, but they are also morphologi-
cally distinct. On electron microscopy, those strains show
variable morphological forms [33,34]. The cell wall of the
TDR TB strains is thicker than that of MDR TB strains with
the appearance of pilus-like structures [35–37]. The need for
further studies to precisely define the TDR TB strains is obvi-
ous. However, in comparison to the amount of data used to
define XDR TB, there may be a need for more studies to dis-
miss or accept the definition TDR TB. In contrast, TDR TB
may represent a dilemma in many clinical settings within
Middle East countries. Considering the limited availability of
drugs in certain geographic regions and the absence of labo-
ratories able to test the susceptibility to additional anti-TB
drugs, it would be convenient to use the acronym TDR TB in
restricted geographic regions in which such strains are
detected as the term reflects the actual therapeutic options.
Surveillance of drug resistance in TB in the Middle
East
The most effective approach to monitor trends in drug resis-
tance in new and previously treated TB cases is by applying
continuous surveillance for MDR TB, through routine DST of
TB patients and systematic collection and analysis of data
[15]. Indeed, the extent of MDR/XDR TB globally was found
to be much higher than previously expected [38]. However,
the global awareness of the risk of spread of drug resistance
patterns was mobilized late [39]. Internationally, an increas-
ing number of countries have established high-quality
surveillance systems to track drug resistance in TB. In
resource-limited settings, routine DST is not accessible to all
TB patients, due to lack of laboratory capacity or resources.
This makes continuous surveillance for MDR TB through rou-
tine DST of TB patients impractical. The recommended alter-
native approach to the continuous surveillance for MDR TB,
through routine DST of TB patients is by conducting surveys
every 5 years to investigate the burden of drug resistance.
Within Middle East countries, in 2014, the first-ever drug-
resistance survey was completed in Iraq and a repeat survey
was completed in Iran [12]. Within Middle East countries, rou-
tine DST is not accessible to all patients. In Qatar, Oman, and
Kuwait, the burden of TB is low, and therefore, all cases (new
and retreatment) were tested for MDR TB. By contrast, in
other countries, the proportion of tested cases was in the
range from 1% to 84% within new cases and from 15% to
60% within the retreatment group of patients. Some countries
such as Palestine did not test any cases [12]. Therefore, in
many Middle East countries, substantial numbers of notified
TB cases are not tested for MDR TB, and thus, unknown num-
bers of MDR TB cases are missed. This may contribute to the
under-reporting of MDR TB in Middle East countries.
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Globally, an estimated 3.3% of new TB cases and 20% of previ-
ously treated cases have MDR TB; a level that has changed lit-
tle in recent years [12]. Similarly, within EMRO countries, the
proportion of MDR TB cases accounted for 3.2% and 18% of
new and previously treated TB cases in 2014, respectively.
The underdetection of MDR TB cases remains a serious chal-
lenge to TB control [40]. Underdetection mainly results from a
low proportion of cases being tested for MDR TB [15,40]. In
2014, only 4.6% of the new cases and 52% of the previously
treated cases were tested for MDR TB.
In Turkey, several population-based and hospital-based
studies have shown that the proportion of drug-resistant TB
cases is higher than the global average [41–46]. For instance,
in a study using 397 M. tuberculosis clinical isolates collected
from Malatya, Turkey, in the period from 2000 to 2007, resis-
tance to any anti-TB drug was found in 29% (114 of 397) of
the study isolates, while the MDR rate was approximately
4.5% (18 of 397). The 2012 report of fighting tuberculosis in
Turkey [47] presented data on the rate of MDR TB cases in
2005, 2009, 2011, and 2012. In 2005, the reported number of
MDR TB patients among newly diagnosed cases, was 101
(3.1%); the MDR TB rate in the retreatment cases was 17.7%
(90 patients); and the MDR TB rate in all cases was 5.1% (191
patients). In 2009, it was reported that the number of MDR
TB patients was 99 (2.7%) among newly diagnosed cases,
and 123 (20.5%) in the retreatment cases, and the total num-
ber of MDR TB cases was 222 (5.1%) [47]. The rate of new
MDRTB caseswas 2.7% (116 people); that of previously treated
patients was 24.3% (146 people); and that of all cases of MDR
TB was 5.4% (262 people) in 2011. In 2012, the rate of newMDR
TB cases was 3.2%; that of patients receiving prior treatment
was 21.8% (140 people); and that of all cases was 5.4% (291
people). According to the WHO report of 2014, the percentage
of estimated MDR TB within the new cases was 2.5% (2.1–3%)
and within the retreatment group, it was 18% (15–21%). The
estimated number of MDR TB cases among the notified pul-
monary TB cases was 190 (160–230) and among the new cases
and 170 (140–200) among the retreatment cases. However, the
number of laboratory confirmed MDR TB cases was 349 cases,
and 257 patients started on MDR TB treatment.
The WHO report of 2015, included the following data on
MDR TB cases in Iran. The percentage of estimated MDR TB
within the new cases was 0.8% (0.3–1.4%) and within the
retreatment group it was 12% (6.2–19%). The estimated num-
ber of MDR TB cases among the notified pulmonary TB cases
was 55 (21–96) and among the new cases, and 76 (38–110)
among the retreatment cases. However, there were 48 labora-
tory confirmed MDR TB cases and 53 patients started on MDR
TB treatment. Within GCC countries, the estimated preva-
lence of MDR TB cases among new TB cases ranged from
1.7% in UAE to 6.3% in Bahrain, whereas estimated prevalence
among retreated cases ranged from 0% in Kuwait and Oman
to 16% in Saudi Arabia [12]. The study of Areeshi et al. [48]
in 2014 discussed the prevalence of drug resistance in clinical
isolates ofM. tuberculosis from GCC countries based on review
and analysis of reports published between January 2002 and
March 2013. The study included 11,393 M. tuberculosis isolatesfrom GCC countries. The highest prevalence rate of MDR TB
was found in UAE (9.2%), followed by Kuwait (5.9%) and Saudi
Arabia (4.3%). The overall MDR TB prevalence rate was
recorded as 4.0% in the entire GCC region [48]. In Kuwait,
Mokaddas et al. [49] in 2008 analyzed the incidence and
trends of drug resistance among allM. tuberculosis strains iso-
lated in Kuwait during a 10-year period, from 1996 to 2005. The
MDR resistance rate was 0.9%, and the rate was almost stable
over the 10-year period. Similar to other Gulf States, most TB
cases were identified in expatriates. In Saudi Arabia, the first
nationwide survey for MDR TB cases [50] allowed a comparison
to be made between the WHO estimates, based on modeling
work, and the nationwide survey. The WHO report of 2011 sug-
gested that 1.2% (0.7–1.6%) and 9.0% (5.6–12.4%) of new and pre-
viously treated cases, respectively, were MDR TB [51]. However,
the national survey showed MDR TB in 1.8% and 15.9% of new
and previously treated TB cases, respectively. This survey con-
firms that the proportion of MDR TB in Saudi Arabia is low,
although the rates were slightly higher than WHO estimates.
In this survey, the strongest independent predictors of MDR
TB were a treatment history of active TB, being foreign-born,
having pulmonary TB, and living in the western part of the
country. According to this survey, it seems that drug resistance
is not a major problem in Saudi Arabia, where the proportion of
MDR TB among newly diagnosed cases is among the lowest
reported globally and in the WHO EMR. Indeed, MDR TB is
not uniformly distributed throughout Saudi Arabia but rather
is more concentrated in the western provinces and in the large
population of immigrant workers.Management of MDR TB and treatment outcomes
in the Middle East
The WHOWorking Group on DOTS-Plus for MDR TB was estab-
lished in 1999 to lead the global effort to control the disease.
DOTS-Plus is a case management strategy under the aegis of
Directly Observed Treatment Short Course (DOTS to manage
MDR TB encompassing two elements: first is the treatment of
the MDR TB patients using second-line drugs; and second are
the measures to control infection. Implementation of effective
DOTS-Plus requires existing efficiently implemented DOTS [52].
The ultimate goals for the DOTS-Plus strategy are to reduce
morbidity and mortality from MDR TB, as well as to cut the
chain of transmission [53]. To ensure that the DOTS-Plus strat-
egy is implemented effectively, the WHO Working Group on
DOTS-Plus established a Green Light Committee (GLC) in June
2000 to lay down the ‘‘Models of Good Practice” for MDR TB
patients. This committee ensures that benchmarks are met
before DOTS-Plus is initiated at any site and also provide tech-
nical support for implementing DOTS-Plus protocols. One
major function of this committee is to collaborate with
second-line drug manufacturers to maintain a continuous sup-
ply of quality-assured drugs at affordable rates [54]. Countries
that meet the framework requirements, with a strong DOTS
foundation and a solid plan to manage drug-resistant TB, can
benefit from quality-assured second-line drugs at reduced
prices. The GLC also offers technical assistance before imple-
mentation of drug-resistant TB control programs and monitors
approved projects.
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for a total of 522 notified MDR TB cases started on treatment in
2012. The country cohort size ranged from two to 291 cases. Six
countries reported outcomes for >10 MDRTB cases per country.
The treatment success rates were in the range from 20% in
Saudi Arabia to 66% in Turkey. The number of cases reported
in annual cohorts has steadily increased. Except for Saudi Ara-
bia, the proportion of failures, defaulters, and deaths are com-
parablewith the average treatment success rate reachedwithin
the GLC projects and with other reported studies [12].
In a retrospective study in Iran, all MDR TB patients hospi-
talized at a tertiary hospital in Tehran, Iran, during 2004–2007
were recruited. Fifty-one patients were included, 12 with XDR
TB criteria. Successful outcome was 81.2% in patients with
MDR TB in comparison with 41.6% in patients with XDRTB [55].
The study of Gadallah et al. [56] in 2015 represents the first
Egyptian national treatment cohort of MDR TB from 2006 to
2010. In this cohort, the number of laboratory-confirmed
MDR TB cases was 228; of which, 225 were pulmonary cases.
A total of 158 (119 cured and 39 completed treatment) patients
achieved a successful outcome (69.3%), 16 (7.1%) failed treat-
ment, 27 (11.8%) were lost to follow-up, and 27 (11.8%) died.
Predictors of unsuccessful outcomewere delay in sputum cul-
ture conversion to P2 months, moderate or extensive lung
lesions, and a history of diabetes [56].
Second-line DST
Owing to the increased proportion of XDR TB cases detected
globally, patients with MDR TB require DST for second-line
drugs to refine and optimize their treatment regimen. Indeed,
one of the targets included in the Global Plan to Stop TB 2011–
2015was that by 2015, all patients with MDRTB would be tested
for XDR TB [14]. However, this target seemed far from being
achieved in most of the Middle East countries due to the lack
of capacity to perform second-line DST. Iran, Egypt, Oman, Tur-
key, and UAE have built in-country capacity for second-line DST,
whereas Iraq, Qatar, Lebanon, and Palestine rely on partner lab-
oratories outside the country (including WHO Supranational
Reference Laboratories) for such testing. However, Kuwait, Jor-
dan, Saudi Arabia, Syria, and Yemen with reported MDR TB
cases indicated that they had neither in-country capacity nor
a linkage with a partner laboratory for second-line DST [12].
Epidemiology of XDR-TB in the Middle East
The first description of XDR TB cases was in 2006 by the US
Centers for Disease Control and Prevention [57]. A serious
nosocomial outbreak of XDR TB was identified in 2005 at the
Church of Scotland Hospital in Kwazulu-Nata, Tugela Ferry,
South Africa. The strains responsible for this outbreak were
rapidly fatal with a mortality rate of 98% [58]. By the end of
2014, 105 countries had reported cases of XDR TB. The average
percentage of XDR TB cases among MDR TB cases was 9.7%. A
total of 49 countries and territories are reported to treating
people with XDR TB [12].
Within the Middle East, several countries have docu-
mented the existence of XDR TB cases. In Turkey, nine XDR
TB cases were reported in the period from 2010 to 2012. Threeof these patients were born in Turkey, while the other three
were born outside of Turkey [47]. Within the GCC, only Oman
has reported data on XDR TB; reporting four cases of XDR TB
that started second-line treatment in 2012, and by 2014, only
two showed treatment success. In Iran, XDR cases are fre-
quently reported [55,59,60]. The study of Masjedi et al. [59]
represents 2 years surveillance in a tertiary health center to
determine the existence and transmission of XDR TB among
patients with MDR TB in Iran. In that study, testing of suscep-
tibility to first-line drugs for 1284 M. tuberculosis isolates
revealed the existence of 113 MDR TB cases. Susceptibility
testing of the MDR TB strains for second-line drugs showed
the presence of 12 (10.9%) XDR TB cases. They performed
genotypic investigations to figure out the genetic relatedness
among the XDR TB isolates and found that all of them
belonged to one of two epidemiological clusters: either a
single-family cluster (4 cases) or a cluster of close contacts
(8 cases). In either of the two clusters, the index patients
acquired the XDR TB strains from an individual infected by
MDR TB strains and transmitted it to their contacts [59].
Management of XDR TB patients
Treatment of XDR TB patients is problematic and frequently
requires at least 18–24months of four to six second-line anti-
TB drugs. Globally, a total of 49 countries and territories are
reported to be treating people with XDR TB, and 41 countries
reported outcomes for cohorts from 2012. In those cohorts,
there were 2685 XDR TB patients. A total of 682 (26%) had com-
pleted treatment successfully; 809 (30%) died; treatment failed
for 510 (19%); and 684 (25%) were lost to follow-up or their treat-
ment outcome was not evaluated [12]. This low global success
rate in treating XDR TB indicates the urgent need for more
effective regimens. Within EMRO countries, there were 43
XDR TB cases started on second-line treatment in 2012, which
showed a treatment success rate of 33%.
Within Middle East countries, only three countries are
reporting outcomes of treatment of XDR TB cases: Turkey,
Iran, and Oman. In 2015, Turkey and Oman reported the treat-
ment outcomes of eight XDR TB cases that started treatment
in 2012. In Turkey, the cohort included six cases, and four of
them completed treatment successfully. In Oman, the cohort
comprised two cases, and one was treated successfully [12].
This treatment success rate is higher than the global rate. In
Iran, the report of Tabarsi et al. [55] discussed the treatment
outcome of MDR non-XDR TB (39 patients) and XDR TB (12
patients) from 2004 to 2007. The treatment success rate was
87.2% in the MDR non-XDR TB cases, whereas it dropped to
41.7% in the XDR TB cases.
Application of molecular methods for rapid
diagnosis of drug resistance in the Middle East
Clearly, there is under-reporting of MDR/XDR TB cases in Mid-
dle East countries. One reason for this is the limited capacity
of the infrastructure to provide widespread coverage of DST
services. The use of molecular methods and technologies is
a potential alternative to conventional DST, especially at
lower levels of the health system. Over the past 20 years, sev-
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the rapid identification of MDR/XDR TB cases in the Middle
East [61–67]. Two rapid molecular assays were endorsed by
WHO for diagnosis of TB and drug resistance: line-probe
assays and Xpert MTB/RIF. At present, the real-time poly-
merase chain reaction assay for rifampin resistance, Xpert
MTB/RIF test (Cepheid, Sunnyvale, CA, USA), is the only
mature fully automated technology that has the ability to per-
form simultaneous detection of TB and resistance to rifampi-
cin [14]. The utility of both technologies was reported in
several field and experimental studies [68]. In 2010, WHO rec-
ommended the use of Xpert MTB/RIF for initial diagnosis of
patients suspected to have MDR TB or HIV-associated TB
(strong recommendations) [51]. After being endorsed and rec-
ommended by WHO, the use of Xpert MTB/RIF has been
quickly expanded within many countries. By the end of
December 2014, WHO data showed that a total of 3763 Xpert
devices had been introduced into the public services in 116
of the 145 countries entitled for concessional pricing [12].
Field studies have documented the positive impact of Xpert
expansion in improving case-finding and detection of drug
resistance [69].
Despite the WHO recommendation for the use of Xpert
MTB/RIF technology and its expanded usages, a limited number
of Middle East countries have purchased this technology. Tur-
key and Iraq have the highest number of registered site per-
forming Xpert MTB/RIF (24 and 11 sites, respectively). Iran has
three sites and Jordan has a single site. The other Middle East
countries have not yet any registered site performing this tech-
nology. Surprisingly, none of the GCC countries has reported or
registered a site to perform Xpert MTB/RIF. While some coun-
tries cannot afford to use Xpert MTB/RIF, due to economic
crises, such as in Yemen and Syria, it is not clear why other
wealthy countries have not yet introduced this technology.
Conclusion
There is obvious under-reporting of MDR/XDR TB cases in the
Middle East. The low coverage of DSTwithinmany of theMiddle
East countries is one of the main constraints limiting the detec-
tion of MDR TB among people diagnosed with TB. Only a small
proportion of new bacteriologically confirmed TB cases, as well
as those treated for TB, were tested for MDR TB. This indicates
that access to TB laboratory services within Middle East coun-
tries is low and below the target envisaged by WHO planning.
Expanding the coverage of diagnostic DST is an immediate
requirement to enhance the detection of MDR and XDR TB.
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